

REFERENCES AND AUTHOR NOTES

INTRODUCTION

1. R. Steiner. *How to Know Higher Worlds: A Modern Path of Initiation* (CW 10). Hudson, NY: Anthroposophic Press, 1994.
2. H. J. Hamre, et al. "Use and safety of anthroposophic medicinal products: an analysis of 44,662 patients from the EvaMed Pharmacovigilance Network. *Drugs: Real World Outcomes* 4, 199–213 (2017). <https://doi.org/10.1007/s40801-017-0118-5>.
3. Qi Zhang, et al. "The path toward integration of traditional and complementary medicine into health systems globally: The World Health Organization report on the implementation of the 2014–2023 strategy," PMID: 31525106 DOI: 10.1089/acm.2019.29077.jjw.
4. A. Chaudhary and N. Singh. "Contribution of World Health Organization in the global acceptance of ayurveda," *Journal of Ayurveda and Integrative Medicine*, 2011(2):179–186.
5. M. A. Horneber, et al. "Mistletoe therapy in oncology," *Cochrane Database Syst Rev*, 2008:CD003297. DOI: 10.1002/14651858.CD003297.pub2.
6. M. Kröz, et al. "Validation of the German version of the cancer fatigue scale (CFS-D)," *Eur. J. Cancer Care*, 2008;17:33–41. DOI: 10.1111/j.1365-2354.2007.00799.x.
7. Per data published by Mistletoe-Therapy.org. "Currently 154 studies have been conducted on the anthroposophical mistletoe preparations abnobaVISCUM, Helixor, Iscador and Iscucin (status May 2020)," accessed Apr. 26, 2021.

CHAPTER 1

1. J. Wilkens and G. Böhm. *Mistletoe Therapy for Cancer: Prevention, Treatment, and Healing* (Edinburgh: Floris Books, 2010), p. 23.
2. Ibid.
3. M. Wood. *The Earthwise Herbal, vol. 1: A Complete Guide to Old World Medicinal Plants*. Berkeley, CA: North Atlantic Books, 2008.
4. Imhotep case 45: Breasted, *Edwin Smith Papyrus*.
5. H. E. Sigerist. "The historical development of the pathology and therapy of cancer," *Bulletin of the New York Academy of Medicine* 8, no. 11 (1932): 642–53.
6. C. Galen. *Methodus Medendi, with Brief Declaration of the Worthie Art of Medicine, the Office of a Chirgion, and an Epitome of the Third*

- Booke of Galen, of Naturall Faculties*. London: Thomas East, 1586, pp. 180–182.
7. S. Mukherjee. *The Emperor of all Maladies: A Biography of Cancer* (New York: Simon and Schuster, 2011), pp. 47–49.
8. B. Krone, et al. “The biography of the immune system and the control of cancer: from St Peregrine to contemporary vaccination strategies,” *BMC Cancer*, 14, Article number: 595 (Aug. 14, 2014).
9. G. L. Rohdenburg, “Fluctuations in the Growth Energy of Malignant Tumors in Man, with Especial Reference to Spontaneous Recession,” *The Journal of Cancer Research*, Apr. 1, 1918; 3(2):193–225. doi: 10.1158/jcr.1918.193.
10. B. Wiemann and C. O. Starnes. “Coley’s toxins, tumor necrosis factor and cancer research: A historical perspective,” *Pharmacology and Therapeutics*, vol. 64, no. 3, 1994, pp. 529–564, ISSN 0163-7258, [https://doi.org/10.1016/0163-7258\(94\)90023-X](https://doi.org/10.1016/0163-7258(94)90023-X).
11. A. Szurpnicka, et al. “Biological activity of mistletoe: in vitro and in vivo studies and mechanisms of action,” *Arch. Pharm. Res.* (2020) 43:593–629 Online ISSN 1976-3786 <https://doi.org/10.1007/s12272-020-01247-w>.
12. B. Barlow. “Mistletoe in folk legend and medicine,” *Australian National Herbarium*, Aug. 7, 2008; posted <https://www.anbg.gov.au/mistletoe/folk-legend.html>. Retrieved Apr. 30, 2021.
13. M. Grieve. *A Modern Herbal: vol. 2, I–Z and Indexes*, New York: Dover, 1971. Digital version of entry “Mistletoe,” at <https://www.botanical.com/botanical/mgmh/m/mistle40.html>. Retrieved Apr. 29, 2021.
14. U. Pfüller. “Chemical constituents of European mistletoe (*Viscum album* L.), in A. Büssing (ed.), *Mistletoe: The Genus Viscum* (Amsterdam: Harwood Academic, 2000), pp. 101–122.
15. G. S. Kienle and H. Kiene. *Mistletoe in Oncology: Facts and Basic Concepts*, New York: Schatauer, 2003.
16. M. Giudici, et al. “Interaction of viscotoxins A3 and B with membrane model systems: Implications to their mechanism of action,” *Biophys. J.*, 2003 Aug;85(2):971–81. doi: 10.1016/S0006-3495(03)74536-6. PMID: 12885644; PMCID: PMC1303218.
17. M. Yang and W. J. Brackenbury. “Membrane potential and cancer progression,” *Front Physiol.*, 2013 Jul 17;4:185. doi: 10.3389/fphys.2013.00185. PMID: 23882223; PMCID: PMC3713347.
18. M. Hashemzaei, et al. “Anticancer and apoptosis-inducing effects of quercetin in vitro and in vivo,” *Oncol. Rep.*, 2017 Aug;38(2):819–828. doi: 10.3892/or.2017.5766. Epub 2017 Jun 28. PMID: 28677813; PMCID: PMC5561933.
19. H. Becker and J. M. Scher. “Short survey of the main components of European mistletoe (*Viscum album* L.),” in R. Scheer. et al (eds.), *Fortschritte in Der Misteltherapie*, Essen: KVC Verlag, 2005.
20. A. Szurpnicka, et al. “Biological activity of mistletoe: in vitro and in vivo studies and mechanisms of action,” *Arch. Pharm. Res.* (2020) 43:593–629 Online ISSN 1976-3786 <https://doi.org/10.1007/s12272-020-01247-w>.

21. S. K. Ghosh. "Giovanni Battista Morgagni (1682–1771): Father of pathologic anatomy and pioneer of modern medicine," *Anatomical Science International*, vol. 92,3 (2017): 305–312. doi:10.1007/s12565-016-0373-7.
22. Y. Kaya and A. Sindel. "John Hunter (1728–1793) and his legacy to science," *Childs Nerv. Syst.*, 32, 1015–1017 (2016). <https://doi.org/10.1007/s00381-015-2852-x>.
23. L. Tonetti. "The discovery of the lymphatic system as a turning point in medical knowledge: Aselli, Pecquet, and the end of hepatocentrism," *Journal of Theoretical and Applied Vascular Research* (2017);2(2):67–76.
24. P. Pott and J. Earles. *The Chirurgical Works of Percivall Pott, F.R.S. Surgeon to St. Bartholomew's Hospital, A New Edition*, London: Wood and Innes, 1808, 3:177.
25. R. D. Passey. "Experimental soot cancer," *The British Medical Journal*, 1922, 2 (3232): 1112–1113.
26. A. Dronsfield. "Percivall Pott, chimney sweeps and cancer," *Education in Chemistry*, vol. 43 no. 2. Royal Society of Chemistry, 2006. pp. 40–42, 48.
27. J. H. Wiener. *Great Britain: The Lion at Home: A Documentary History of Domestic Policy, 1689–1973*, New York: Chelsea House, 1974.
28. "Johannes Müller (1801–1858), anatomist, physiologist, pathologist," *JAMA*, vol. 214,11 (1970): 2049–51.
29. M. Schultz. "Rudolf Virchow," *Emerging Infectious Diseases*, vol. 14,9 (2008): 1480–1481. doi:10.3201/eid1409.086672.
30. R. R. Langley and I. J. Fidler. "The seed and soil hypothesis revisited: The role of tumor-stroma interactions in metastasis to different organs," *International Journal of Cancer*, vol. 128,11 (2011): 2527–35. doi:10.1002/ijc.26031.
31. Ibid.
32. Ibid.
33. P. Ehrlich. "Ueber den jetzigen Stand der Karzinomforschung," *Ned. Tijdschr. Geneesk.*, 5 (1909), pp. 273–290.
34. G. P. Dunn, et al. "The immunobiology of cancer immunosurveillance and immunoediting," *Immunity*, vol. 21, no. 2, 2004, pp. 137–148.
35. Quangdon Tran, et al. "Revisiting the Warburg effect: Diet-based strategies for cancer prevention," *BioMed Research International*, vol. 2020 8105735. 4 Aug. 2020, doi:10.1155/2020/8105735.
36. T. Boveri. *Concerning the Origin of Malignant Tumors*, New York: Cold Spring Harbor, 2006.
37. V. Wunderlich. "Early references to the mutational origin of cancer," *International Journal of Epidemiology*, vol. 36, no. 1, Feb. 2007, pp. 246–247, <https://doi.org/10.1093/ije/dyl272>.
38. "Cancer mutations occur decades before diagnosis," European Molecular Biology Laboratory, Feb. 4, 2020; online at <https://www.ebi.ac.uk/about/news/announcements/cancer-mutations-decades-before-diagnosis>. Retrieved Apr. 29, 2021.
39. W. C Röntgen. "On a new kind of rays," *Nature*, 53, no. 1369 (1896): 274–76.

40. E. H. Grubbe. "Priority in therapeutic use of X-rays," *Radiology*, 21 (1933): 156-62.
41. W. S. Halsted. "The results of radical operations for the cure of cancer of the breast," *Transactions of the American Surgical Association* 25: 66.
42. L. F. Vernon. "William Bradley Coley, MD, and the phenomenon of spontaneous regression," *Immunotargets Ther.*, 2018;7:29-34. <https://doi.org/10.2147/ITT.S163924>.
43. E. F. McCarthy. "The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas," *The Iowa Orthopaedic Journal*, vol. 26 (2006): 154-8.
44. S. A. Hoption Cann, et al. "Dr William Coley and tumour regression: A place in history or in the future," *Postgraduate Medical Journal*, 2003;79:672-680.
45. R. Steiner. *Introducing Anthroposophical Medicine* (CW 312). Great Barrington, MA: SteinerBooks; 2010.
46. C. Murphy. *Iscador: Mistletoe and Cancer Therapy*. New York: Lantern Books, 2001. (AUTHOR NOTE: Ita Wegman was instrumental in developing the first recognized mistletoe extract product, Iscador®. Her story is covered in greater depth at <https://www.mistletoe-therapy.org/information-for-patients/preparations/iscador>.)
47. G. S. Kienle, et al. "Individualized integrative cancer care in anthroposophic medicine: A qualitative study of the concepts and procedures of expert doctors," *Integrative Cancer Therapies*, May 4, 2016, 15(4):478-494. DOI: 10.1177/1534735416640091 PMID: 27151589 PMCID: PMC5739166.
48. R. Steiner. lecture of Oct. 27, 1922 p.m., in *Physiology and Healing: Treatment, Therapy, and Hygiene* (CW 314). Forest Row, UK: Rudolf Steiner Press, 2014.
49. R. A. Weinburg. *The Biology of Cancer*, 2nd ed. (New York: Garland Science, 2014), 15(13).
50. R. R. Bartelme. "Anthroposophic Medicine: A Short Monograph and Narrative Review: Foundations, Essential Characteristics, Scientific Basis, Safety, Effectiveness and Misconceptions." *Global Advances in Health and Medicine*. vol. 9 2164956120973634. 29 Dec. 2020, doi:10.1177/2164956120973634.
51. J. Conant. *The Great Secret: The Classified World War II Disaster that Launched the War on Cancer*. New York: Norton, 2020.
52. S. Farber. "Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (aminopterin)," *New England Journal of Medicine*, 238 (1948): 787-93.
53. D. R. Miller. "A Tribute to Sidney Farber—the Father of Modern Chemotherapy," *British Journal of Haematology*, 134 (2006): 20-26.
54. F. M. Burnet. "The concept of immunological surveillance," *Prog. Exp. Tumor Res.* 1970;13:1-27.
55. M. Burnet. "Immunological factors in the process of carcinogenesis." *Br. Med. Bull.* 1964;20:154-158.

56. M. Smyth, et al. "A fresh look at tumor immunosurveillance and immunotherapy," *Nat. Immunol.*, 2, 293–299 (2001). <https://doi.org/10.1038/186297>.
57. B. M. J.issell, et al. "How does the extracellular matrix direct gene expression?" *J. Theor. Biol.* 99, 31–68 (1982).
58. M. J. Bissell and M. A. Labarge. "Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment?" *Cancer Cell*, vol. 7,1 (2005): 17–23. doi:10.1016/j.ccr.2004.12.013.
59. A. L. Correia and M. J. Bissell. "The tumor microenvironment is a dominant force in multidrug resistance," *Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy*, vol. 15,1–2 (2012): 39–49. doi:10.1016/j.drug.2012.01.006.
60. M. J. Bissell and W. C. Hines. "Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression," *Nature medicine*, vol. 17,3 (2011): 320–9. doi:10.1038/nm.2328.
61. E. Schickler. "Ein neues Mittel gegen Carcinom," [A new remedy against cancer]; Case report series (German), 1924.
62. R. A. Weinburg. *The Biology of Cancer*, 2nd ed. New York: Garland Science, 2014.
63. E. Schickler. "Ein neues Mittel gegen Carcinom" [A new remedy against cancer], Case report series (in German), 1924.
64. G. Salzer and L. Havelec. "Rezidivprophylaxe bei operierten Bronchuskarzinompatienten mit dem Mistelpräparat Iscador Ergebnisse eines klinischen Versuchs aus den Jahren 1969–1971" [Prevention of recurrence of bronchial carcinomas after surgery by means of the mistletoe extract Iscador. Results of a clinical study from 1969–1971]. *Onkologie*, vol. 1,6 (1978): 264–7. doi:10.1159/000213966.
65. G. Kelter and H. H. Fiebig. "Absence of tumor growth stimulation in a panel of 26 human tumor cell lines by mistletoe (*Viscum album* L.) extracts Iscador in vitro," *Arzneimittelforschung* 56 (6A): 435–40, 2006.
66. A. Szurpnicka, et al. "Biological activity of mistletoe: in vitro and in vivo studies and mechanisms of action," *Arch. Pharm. Res.* (2020) 43:593–629; online <https://doi.org/10.1007/s12272-020-01247-w>.
67. J. M. Braun, et al. "Standardized mistletoe extract augments immune response and down-regulates local and metastatic tumor growth in murine models," *Anticancer Res*, 22 (6C): 4187–90, Nov.–Dec. 2002.
68. A. Pulliero, et al. "Genetic and Epigenetic Effects of Environmental Mutagens and Carcinogens," *BioMed Research International*, vol. 2015 (2015): 608054. doi:10.1155/2015/608054.
69. "NIH complementary and integrative health agency gets new name," NCCIH Press Office, Dec. 17, 2014; online at <https://www.nih.gov/news-events/news-releases/nih-complementary-integrative-health-agency-gets-new-name>. Accessed Apr. 26, 2021.
70. P. Barnes, et al. "CDC advance data report #343. Complementary and alternative medicine use among adults: United States, 2002." U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics; May 27, 2004.

71. N. N. Sanford, et al. "Prevalence and nondisclosure of complementary and alternative medicine use in patients with cancer and cancer survivors in the United States." *JAMA Oncology*, vol. 5,5 (2019): 735-737. doi:10.1001/jamaoncol.2019.0349.
72. C. A. Buckner, et al. "Complementary and alternative medicine use in patients before and after a cancer diagnosis." *Current Oncology* (Toronto), vol. 25,4 (2018): e275-e281. doi:10.3747/co.25.3884.
73. C. M. Witt, et al. "A Comprehensive Definition for Integrative Oncology," *JNCI Monographs*, vol. 2017, no. 52, Nov. 2017, lxxii, <https://doi.org/10.1093/jncimonographs/lxxii>.
74. Per Society for Integrative Oncology website, www.integrativeonc.org. Accessed Apr. 26, 2021.
75. T. N. Seyfried and L. M. Shelton. "Cancer as a metabolic disease," *Nutrition and Metabolism* (London) 2010, 7:7. <http://www.nutritionandmetabolism.com/content/7/1/7>.
76. L. G. Boros, et al. "Submolecular regulation of cell transformation by deuterium depleting water exchange reactions in the tricarboxylic acid substrate cycle." *Medical Hypotheses*, vol. 87 (2016): 69-74. doi:10.1016/j.mehy.2015.11.016.
77. A. M. Soto and C. Sonnenschein. "The tissue organization field theory of cancer: A testable replacement for the somatic mutation theory," *BioEssays: News and Reviews in Molecular, Cellular and Developmental Biology*, vol. 33,5 (2011): 332-40. doi:10.1002/bies.201100025.
78. T. N. Seyfried. "Cancer as a mitochondrial metabolic disease," *Frontiers in Cell and Developmental Biology*, vol. 3 43. July 7, 2015, doi:10.3389/fcell.2015.00043.
79. Registered at <https://clinicaltrials.gov/ct2/show/NCT03051477>. Accessed Apr. 26, 2021.
80. A. Brodsky, "Cancer immunotherapy in 2020 and beyond," Cancer Research Institute, at <https://www.cancerresearch.org/blog/january-2020/cancer-immunotherapy-in-2020-and-beyond>. Retrieved Apr. 29, 2021.
81. S. Kruger, et al. "Advances in cancer immunotherapy 2019: Latest trends," *J. Exp. Clin. Cancer Res.*, 38, 268 (2019). <https://doi.org/10.1186/s13046-019-1266-0>.
82. AUTHOR NOTE: The data collection project is already underway for this project. Covered in greater detail in chap. 12.
83. Per data published by Mistletoe-Therapy.org, "Currently 154 studies have been conducted on the anthroposophical mistletoe preparations abnobaviscum, Helixor, Iscador and Iscucin (status May 2020)." Accessed Apr. 26, 2021.
84. C. Murphy, *Iscador: Mistletoe and Cancer Therapy*. New York: Lantern Books, 2001, p. 15.
85. "European Mistletoe," National Institute of Health (NIH) National Center for Complementary and Integrative Health (NCCIH)," digital fact sheet, Aug. 2020. At <https://www.nccih.nih.gov/health/european-mistletoe>. Retrieved Apr. 29, 2021.
86. *Vademecum of Anthroposophic Medicines*, Association of Anthroposophic Medicine in Germany (GAAD); 2017, 82-89.

87. P. J. Mansky, et al. "NCCAM/NCI phase 1 study of mistletoe extract and gemcitabine in patients with advanced solid tumors." *Evidence-based Complementary and Alternative Medicine: eCAM*, vol. 2013 (2013): 964592. doi:10.1155/2013/964592.
88. R. Madeley, et al. "Hirntumore bei Kindern: Therapieverläufe (Teil I)" [Brain tumors in children: therapy courses (Part 1)] *Der Merkurstab. Beiträge zur einer Erweiterung der Heilkunst*. 2001;54(6):397-407.
89. Ibid. (Teil II)." [Brain tumors in children: therapy courses (Part 2)] *Der Merkurstab. Beiträge zur einer Erweiterung der Heilkunst*. 2002;55(1):36-47.
90. A. J. Husemann and A. Orle. "Misteltherapie bei Riesenzellastrozytom" [Mistletoe therapy for giant cell astrocytoma"], *Der Merkurstab. Beiträge zur einer Erweiterung der Heilkunst* 2000;53(3):183.
91. *Vademecum of Anthroposophic Medicines*. Published by Association of Anthroposophic Medicine in Germany (GAAD); 2017, 82-89.
92. K. Hostanska, et al. "Recombinant mistletoe lectin induces p53-independent apoptosis in tumour cells and cooperates with ionising radiation," *Br. J. Cancer*. 2003 Jun 2;88(11):1785-92. doi: 10.1038/sj.bjc.6600982. PMID: 12771996; PMCID: PMC2377150.
93. J. E. Felenda, et al. "Antiproliferative potential from aqueous *Viscum album* L. preparations and their main constituents in comparison with ricin and purothionin on human cancer cells," *Journal of Ethnopharmacology*, vol. 236, 2019, pp. 100-107; <https://doi.org/10.1016/j.jep.2019.02.047>.
94. G. S. Kienle and H. Kiene. "Review article: Influence of *Viscum album* L. (European mistletoe) extracts on quality of life in cancer patients: a systematic review of controlled clinical studies," *Integr Cancer Ther*, 2010;9:142-157. doi: 10.1177/1534735410369673.
95. B. K. Piao, et al. "Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients: A prospective randomized controlled clinical trial," *Anticancer Research*, 2004;24:303-310.
96. Quangdon Tran, et al. "Revisiting the Warburg Effect: Diet-Based Strategies for Cancer Prevention." *BioMed Research International*, vol. 2020 8105735. 4 Aug. 2020. doi:10.1155/2020/8105735.
97. T. Seyfried, *Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer*, Hoboken, NJ: Wiley, 2012.
98. N. K. LoConte, et al. "Lifestyle modifications and policy implications for primary and secondary cancer prevention: Diet, exercise, sun safety, and alcohol reduction," *American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting*, vol. 38 (2018): 88-100. doi:10.1200/EDBK_200093.
99. J. R. Infante, et al. "Levels of immune cells in transcendental meditation practitioners," *International Journal of Yoga*, vol. 7,2 (2014): 147-51. doi:10.4103/0973-6131.133899.
100. Jiang Shui, et al. "Epigenetic modifications in stress response genes associated with childhood trauma," *Frontiers in Psychiatry*, vol. 10 808, Nov. 8, 2019. doi:10.3389/fpsy.2019.00808.